Argus Upgrades Affymax (AFFY) to Buy
More News related to AFFY
- Affymax to Present at Piper Jaffray 21st Annual Healthcare Conference
- Affymax (AFFY) Closes Stock Offering, Receiving Net Proceeds of $80M
- Affymax Announces Close of Common Stock Offering and Exercise of Underwriters' Overallotment Option
- Affymax (AFFY) Prices 4.1M Shares at $18.25/Share
- Affymax Prices Public Offering of Common Stock
More News related to Upgrades
- Shares of Brocade (BRCD) Outperforming as Oscar Gruss Upgrades to Buy
- Kinross (KGC) Jumps Higher as Gold Breaks $1,200, JPMorgan Upgrades to Overweight
- Raymond James Upgrades PSS World Medical (PSSI) to Outperform
- Capital One Southcoast Upgrades Penn Virginia (PVA) to Add; Turning Bullish After Data Release
- Raymond James Upgrades CPFL Energia S.A. (CPL) to Outperform
Argus upgrades Affymax (Nasdaq: AFFY) from Hold to Buy.
To see more analyst ratings on AFFY Click Here.
Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions.
Related Categories
UpgradesStocks Mentioned
+1.51Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
